Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer

NCT02919969 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02919969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02919969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2016
Completion date
March 31, 2023
Enrollment
38 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer